RaQualia Pharma Inc. (4579.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.0x

Market Cap

JPY 13.03B

MomentumView details →

1D Return

+0.92%

YTD Return

−45.64%

RSI (14)

55.2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.0x

Market Cap

JPY 13.03B

RSI (14)

55.2

MomentumView details →

1D Return

+0.92%

YTD Return

−45.64%

ProfitabilityView details →

Gross Margin

—

Net Margin

6.86%

EBITDA Margin

17.24%

ROE (TTM)

3.96%

ROA (TTM)

2.60%

Asset Turnover

0.40x

GrowthView details →

Revenue YoY

+28.07%

EPS YoY

+147.65%

FCF YoY

—

Revenue CAGR 3Y

+10.89%

EPS CAGR 3Y

−30.60%

EBITDA YoY

+4739.88%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.38x

Current Ratio

4.46x

Quick Ratio

4.46x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

3.81B

Net Income (TTM)

53.00M

Op. CF (TTM)

203.60M

Next earningsNov 6, 2026 →

Latest newsMore news →

RaQualia Pharma received a patent allowance in South Korea for a TRPV4 antagonist (pyrimidine-4(3H)-one derivative).2d ago

RaQualia Pharma obtains new indication approval in South Korea for tegoprazan: prevention of peptic ulcers associated with NSAID administration.40d ago

Similar companies

TAIKO PHARMACEUTICAL CO.,LTD.4574.T AnGes,Inc.4563.T STELLA PHARMA CORPORATION4888.T Renascience Inc.4889.T MediciNova,Inc.4875.T CanBas Co.,Ltd.4575.T Find similar companies →

Latest newsMore news →

RaQualia Pharma received a patent allowance in South Korea for a TRPV4 antagonist (pyrimidine-4(3H)-one derivative).2d ago RaQualia Pharma obtains new indication approval in South Korea for tegoprazan: prevention of peptic ulcers associated with NSAID administration.40d ago